Cargando…

Dopamine D(2) Receptor Agonist Binding Kinetics—Role of a Conserved Serine Residue

The forward (k(on)) and reverse (k(off)) rate constants of drug–target interactions have important implications for therapeutic efficacy. Hence, time-resolved assays capable of measuring these binding rate constants may be informative to drug discovery efforts. Here, we used an ion channel activatio...

Descripción completa

Detalles Bibliográficos
Autores principales: Ågren, Richard, Stepniewski, Tomasz Maciej, Zeberg, Hugo, Selent, Jana, Sahlholm, Kristoffer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8071183/
https://www.ncbi.nlm.nih.gov/pubmed/33920848
http://dx.doi.org/10.3390/ijms22084078
_version_ 1783683641218433024
author Ågren, Richard
Stepniewski, Tomasz Maciej
Zeberg, Hugo
Selent, Jana
Sahlholm, Kristoffer
author_facet Ågren, Richard
Stepniewski, Tomasz Maciej
Zeberg, Hugo
Selent, Jana
Sahlholm, Kristoffer
author_sort Ågren, Richard
collection PubMed
description The forward (k(on)) and reverse (k(off)) rate constants of drug–target interactions have important implications for therapeutic efficacy. Hence, time-resolved assays capable of measuring these binding rate constants may be informative to drug discovery efforts. Here, we used an ion channel activation assay to estimate the k(on)s and k(off)s of four dopamine D(2) receptor (D(2)R) agonists; dopamine (DA), p-tyramine, (R)- and (S)-5-OH-dipropylaminotetralin (DPAT). We further probed the role of the conserved serine S193(5.42) by mutagenesis, taking advantage of the preferential interaction of (S)-, but not (R)-5-OH-DPAT with this residue. Results suggested similar k(off)s for the two 5-OH-DPAT enantiomers at wild-type (WT) D(2)R, both being slower than the k(off)s of DA and p-tyramine. Conversely, the k(on) of (S)-5-OH-DPAT was estimated to be higher than that of (R)-5-OH-DPAT, in agreement with the higher potency of the (S)-enantiomer. Furthermore, S193(5.42)A mutation lowered the k(on) of (S)-5-OH-DPAT and reduced the potency difference between the two 5-OH-DPAT enantiomers. Kinetic K(d)s derived from the k(off) and k(on) estimates correlated well with EC(50) values for all four compounds across four orders of magnitude, strengthening the notion that our assay captured meaningful information about binding kinetics. The approach presented here may thus prove valuable for characterizing D(2)R agonist candidate drugs.
format Online
Article
Text
id pubmed-8071183
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-80711832021-04-26 Dopamine D(2) Receptor Agonist Binding Kinetics—Role of a Conserved Serine Residue Ågren, Richard Stepniewski, Tomasz Maciej Zeberg, Hugo Selent, Jana Sahlholm, Kristoffer Int J Mol Sci Article The forward (k(on)) and reverse (k(off)) rate constants of drug–target interactions have important implications for therapeutic efficacy. Hence, time-resolved assays capable of measuring these binding rate constants may be informative to drug discovery efforts. Here, we used an ion channel activation assay to estimate the k(on)s and k(off)s of four dopamine D(2) receptor (D(2)R) agonists; dopamine (DA), p-tyramine, (R)- and (S)-5-OH-dipropylaminotetralin (DPAT). We further probed the role of the conserved serine S193(5.42) by mutagenesis, taking advantage of the preferential interaction of (S)-, but not (R)-5-OH-DPAT with this residue. Results suggested similar k(off)s for the two 5-OH-DPAT enantiomers at wild-type (WT) D(2)R, both being slower than the k(off)s of DA and p-tyramine. Conversely, the k(on) of (S)-5-OH-DPAT was estimated to be higher than that of (R)-5-OH-DPAT, in agreement with the higher potency of the (S)-enantiomer. Furthermore, S193(5.42)A mutation lowered the k(on) of (S)-5-OH-DPAT and reduced the potency difference between the two 5-OH-DPAT enantiomers. Kinetic K(d)s derived from the k(off) and k(on) estimates correlated well with EC(50) values for all four compounds across four orders of magnitude, strengthening the notion that our assay captured meaningful information about binding kinetics. The approach presented here may thus prove valuable for characterizing D(2)R agonist candidate drugs. MDPI 2021-04-15 /pmc/articles/PMC8071183/ /pubmed/33920848 http://dx.doi.org/10.3390/ijms22084078 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Ågren, Richard
Stepniewski, Tomasz Maciej
Zeberg, Hugo
Selent, Jana
Sahlholm, Kristoffer
Dopamine D(2) Receptor Agonist Binding Kinetics—Role of a Conserved Serine Residue
title Dopamine D(2) Receptor Agonist Binding Kinetics—Role of a Conserved Serine Residue
title_full Dopamine D(2) Receptor Agonist Binding Kinetics—Role of a Conserved Serine Residue
title_fullStr Dopamine D(2) Receptor Agonist Binding Kinetics—Role of a Conserved Serine Residue
title_full_unstemmed Dopamine D(2) Receptor Agonist Binding Kinetics—Role of a Conserved Serine Residue
title_short Dopamine D(2) Receptor Agonist Binding Kinetics—Role of a Conserved Serine Residue
title_sort dopamine d(2) receptor agonist binding kinetics—role of a conserved serine residue
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8071183/
https://www.ncbi.nlm.nih.gov/pubmed/33920848
http://dx.doi.org/10.3390/ijms22084078
work_keys_str_mv AT agrenrichard dopamined2receptoragonistbindingkineticsroleofaconservedserineresidue
AT stepniewskitomaszmaciej dopamined2receptoragonistbindingkineticsroleofaconservedserineresidue
AT zeberghugo dopamined2receptoragonistbindingkineticsroleofaconservedserineresidue
AT selentjana dopamined2receptoragonistbindingkineticsroleofaconservedserineresidue
AT sahlholmkristoffer dopamined2receptoragonistbindingkineticsroleofaconservedserineresidue